New Journey (002219.SZ) announced that the company's wholly-owned subsidiary, Kangxian Duyiwei Biological Pharmaceutical Co., Ltd. ("Duyiwei Pharmaceutical"), recently participated in the centralized volume-based procurement tender conducted by the national Chinese Patent Medicine procurement office ("Procurement Office"). According to the announcement of the Procurement Office regarding the proposed selection results for the national Chinese Patent Medicine procurement alliance centralized volume-based procurement, the Duyiwei series products under Duyiwei Pharmaceutical are proposed for selection for the national Chinese Patent Medicine procurement alliance centralized volume-based procurement.
新里程：子公司产品拟中选全国中成药采购联盟集中带量采购
New Journey: The subsidiary's products are planned to be selected for the national Chinese Patent Medicine procurement alliance centralized volume-based procurement.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated